



Immunotherapy. Personalized.

The reality is staggering. One in four dogs will develop cancer in their lifetime. Cancer is the leading cause of death in dogs over the age of two. There's a new hope for these dogs. ELIAS Animal Health is bringing its personalized treatment platform to clinics across the country.


More than 50 dogs have been treated with ELIAS Cancer Immunotherapy (ECI[®]) as an alternative to chemotherapy. The results in the patients which responded to the therapy are inspiring.

More than a vaccine

ECI is distinct from other cancer immunotherapies because of its dual approach to treatment. First, a cancer vaccine pretreatment is used to generate T cells that are tumor-specific. These cells are then activated ex-vivo to generate a large population of personalized "killer" T cells that are infused back into the patient.

Because ECI uses the patient's own immune system, the patient avoids the toxic side effects of radiation and chemotherapies. This personalized approach has the potential to be a platform technology of treating multiple cancer indications.

[Read the case studies here.](#)



T cells have been scientifically proven to be the mediators of cancer immunity. Accordingly, treating cancer patients with high numbers of activated, cancer-specific killer T cells is a scientifically logical immunotherapeutic strategy.

Clinical Trials. Now Enrolling.

ELIAS is currently conducting a follow-up study to pursue licensure of ECI. This fully-funded clinical trial will enroll dogs that have been diagnosed with osteosarcoma but have not yet been treated for their cancer. Learn more at ELIASAnimalHealth.com/ECI-OSA-04.

Learn more at ELIASAnimalHealth.com

